UK markets close in 7 hours 23 minutes

Vaccitech plc (VACC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
14.00-0.45 (-3.11%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close14.45
Open14.16
Bid0.00 x 1000
Ask0.00 x 800
Day's range14.00 - 14.38
52-week range12.25 - 17.99
Volume6,683
Avg. volume16,376
Market cap480.595M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-9.52
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est24.50
  • Globe Newswire

    Vaccitech Announces Data Presentations at AASLD’s Liver Meeting® 2021

    OXFORD, U.K., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced two poster presentations at AASLD’s Liver Meeting® 2021 showcasing clinical data for VTP-300, the Company’s immunotherapeutic in development for the treatment of chronic hepatitis B virus (HBV) infection. The Liver Meeting will be held virtually on November 12-15, 2021. Poster Ti

  • Globe Newswire

    Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World Vaccine Congress Europe

    OXFORD, United Kingdom, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Tom Evans, M.D., Vaccitech’s Chief Scientific Officer will present an update on the Company’s chronic hepatitis B (CHB) immunotherapeutic Phase 1b/2a trial at The World Vaccine Congress Europe on October 21 in Barcelona, Spain. “VTP-300, our immunotherapeutic candi

  • The Telegraph

    Taxpayer takes stake in Oxford vaccine co-creator

    The British taxpayer has become a shareholder in an online store for knitting, an at-home beautician service and the Secret Cinema following an effort to rescue startups struggling to survive the pandemic.